Phase 1/2 × Terminated × Lymphoma, Non-Hodgkin × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT03733249 2023-09-26

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Bellicum Pharmaceuticals

Phase 1/2 Terminated
187 enrolled 8 charts
NCT00290706 2019-05-28

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Northwestern University

Phase 1/2 Terminated
32 enrolled 12 charts
NCT00295880 2017-12-28

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
12 enrolled 14 charts
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
NCT00112723 2016-08-08

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled 12 charts
NCT00006220 2013-02-06

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Washington University School of Medicine

Phase 1/2 Terminated
5 enrolled